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Ion channelopathies in endocrinology: 
recent genetic findings and 
pathophysiological insights
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SUMMARY
Ion channels serve diverse cellular functions, mainly in cell signal transduction. In endocrine 
cells, these channels play a major role in hormonal secretion, Ca2+-mediated cell signaling, 
transepithelial transport, cell motility and growth, volume regulation and cellular ionic content 
and acidification of lysosomal compartments. Ion channel dysfunction can cause endocrine di-
sorders or endocrine-related manifestations, such as pseudohypoaldosteronism type 1, Liddle 
syndrome, Bartter syndrome, persistent hyperinsulinemic hypoglycemia of infancy, neonatal 
diabetes mellitus, cystic fibrosis, Dent’s disease, hypomagnesemia with secondary hipocalce-
mia, nephrogenic diabetes insipidus and, the most recently genetically identified channelopa-
thy, thyrotoxic hypokalemic periodic paralysis. This review briefly recapitulates the membrane 
action potential in endocrine cells and offers a short overview of known endocrine channelopa-
thies with focus on recent progress regarding the pathophysiological mechanisms and functio-
nal genetic defects. Arq Bras Endocrinol Metab. 2010;54(8):673-81
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SUMÁRIO
Canais iônicos auxiliam diferentes funções celulares, principalmente na transdução de sinal. 
Nas células endócrinas, esses canais têm funções importantes na secreção hormonal, sina-
lização do Ca2+, transporte transepitelial, regulação da motilidade, volume e conteúdo iônico 
celular e da acidificação do compartimento lisossomal (pH). Como esperado, as alterações nos 
canais iônicos podem causar distúrbios endocrinológicos, como pseudo-hipoaldosteronismo 
tipo 1, síndrome de Liddle, síndrome de Bartter, hipoglicemia hiperinsulinêmica da infância, 
diabetes melito neonatal, fibrose cística, doença de Dent, hipomagnesemia com hipocalcemia 
secundária, diabetes insípido nefrogênico e paralisia periódica tirotóxica hipocalêmica. Este 
artigo propõe uma breve revisão das canalopatias endócrinas conhecidas, com foco particular 
nos recentes progressos no conhecimento dos mecanismos fisiopatológicos adquirido a partir 
das alterações funcionais encontradas. Arq Bras Endocrinol Metab. 2010;54(8):673-81
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IntRODUctIOn
Electrophysiological properties, once thought to be exclusive to neuronal and muscle cells, have been 
found to apply to endocrine tissues. In fact, endocrine 
cells carry electrical impulses in the same way other ex-
citable cells do, relying on membrane transport pro-
teins, such as pores, gated channels and pumps, to react 
to signals. Mutations in any of these channel proteins 
can cause dysfunctions that are collectively referred to 
as endocrine channelopathies. Pores are ion-specific 
passages that allow specific ions to diffuse across the 
plasma membrane along the concentration gradient. 
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Gated-channels are a group of ion-specific transport 
proteins that open or close in response to ligand bind-
ing (ligand-gated), voltage changes (voltage-gated) or 
mechanical deformation (mechanically-gated). In gen-
eral, hormones modify ligand-gated channels located at 
the cell surface, which allows the influx of Ca2+ into the 
cell for downstream cascade signaling. Pumps counter-
act the ionic flow from pores and gated channels to 
reestablish the resting membrane potential by inverting 
the ionic concentration differences on both sides of the 
membrane (1). At rest, the inner surface of the mem-
brane is more highly negative than the outer surface, 
typically -70 mV, resulting in a difference in potential 
that can be disrupted by a depolarizing action potential. 
Cells that secrete hormones or sense hormonal reg-
ulation usually produce chemical messengers that are 
transported through the circulatory system, and require 
seconds, minutes or even hours to act. Neuronal cells, 
on the other hand, transmit messages much more quick-
ly and require only thousands of a second for this ac-
tion. Differently from a “wired” neuronal transmission 
in which the rapid propagation works along the synaptic 
cleft, endocrine transmission occurs slowly through-
out the body because hormones are secreted into the 
blood stream and delivered to distant target sites, as if 
in a “wireless” system (2). Both endocrine and neuro-
nal cells, however, can produce electrical impulses, or 
action potentials (AP). Endocrine cells that respond to 
stimuli with action potentials include chromaffin, pan-
creatic and adenohypophyseal cells (3). With the excep-
tion of b-cells that depolarize by closing KATP channels in 
response to increases in the intracellular ratio of ATP/
ADP after a meal, endocrine cell APs are mainly gener-
ated by voltage-dependent ion currents (4,5). 
In general, APs bring Ca2+ into endocrine cells. This 
influx is crucial for refilling the endoplasmic reticulum 
(ER) Ca2+ pool after depletion by hormone-induced 
calcium release (6), which is a mechanism known as 
stimulus-secretion coupling. The upstroke of the ac-
tion potential is the result of the fast activation of the 
voltage-gated Ca2+ channels (VDCC). Slow activation 
of K+ channels along the second half of phase 1 (Figure 1) 
leads to the downstroke. Interestingly, spontaneous ac-
tion potentials can also occur in the absence of agonists, 
such as in excitable gonadotroph cells; such model of 
spontaneous oscillations was first proposed in 1995 by 
Li and cols. (7). The most important ion currents re-
sponsible for altering the membrane potential are those 
derived from delayed rectifying K+ channels, L- and 
T- type Ca2+ channels and calcium activated potassium 
(KCa) channels (8,9). Importantly, KCa channels only 
work when intracellular Ca2+ content is high, especially 
during the release of Ca2+ from the ER (10). Figure 1 
shows a schematic diagram of the AP phases of a repre-
sentative endocrine cell and summarizes the major ion 
currents throughout the waveform (phases 1-4). It is 
worth emphasizing that cells in the endocrine system 
require an action potential with a long duration rather 
than a fast one. 
thyrotoxic hypokalemic periodic paralysis (tPP) 
TPP is an urgent medical condition where patients suffer 
from sudden and reversible loss of muscle strength in the 
limbs and thyrotoxicosis associated with hypokalemia. 
TPP is the most frequent form of acquired acute flaccid 
paralysis in adults. Although it is most prevalent in 
Asian populations, TPP can occur in individuals of any 
ethnicity (11). Hypokalemia does not indicate a depletion 
of the total potassium pool but an increased influx of the 
ion to the intracellular compartment (11). Early and de-
finitive treatment of thyrotoxicosis should be aimed. 
For a decade, we have been searching for TPP 
candidate genes. Our group and others have demon-
strated that mutations in the CACN1AS and SCN4A 
genes, present in familial forms of hypokalemic paraly-
ses (FHypokPP), are not present in patients with TPP 
(11-14). Kir2.x paralogues have constitutive thyroid 
hormone-responsive cis-elements (TREs) in their reg-
ulatory regions, therefore we screened the coding se-
quence of the KCNJ12 (Kir2.2), KCNJ4 (Kir2.3) and 
KCNJ14 (Kir2.4) genes. We performed low-stringency 
PCR and direct sequencing of Kir2.2 and found a new 
paralogue, Kir2.6. This novel channel, encoded by 
KCNJ18 (17p11.1-2), is a functional potassium chan-
nel. This channel is expressed in skeletal muscle and is 
transcriptionally regulated by T3 (15). Six mutations 
in Kir2.6 have been found to be associated with TPP: 
R205H, T354M, K366R, R399X, Q407X and I144fs 
(15). The two most common Kir2.6 mutations (15), 
R399X and Q407X, are located at the C-terminus of 
the channel and lack the PDZ binding domain bound-
aries that interfere with the assembly either as homo-
tetramers or heterotetramers, and trafficking of the 
complex to the membrane (16). We proposed that TPP 
pathophysiological mechanism is the loss of function of 
the Kir channel reducing the outward potassium cur-
rent, which leads to depolarization and subsequent loss 
of muscle excitability (Figure 2).
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table 1. Ion channel defects associated with endocrine disorders. Data from OMIM (Online Mendelian Inheritance in Man), NCBI (National Center for 
Biotechnology Information), HGMD (Human Gene Mutation Database) and Ensembl websites
channel Gene chromosome RefSeq ID(ncBI) Disorder
n. of 
mutations 
(HGMD)
Functional defect First published reference
ENaCα SCNN1A 12p13 NM_001038 Pseudohypoaldosteronism 
type 1
23 Renal salt loss Chang and cols., 
1996 (13)
ENaCb SCNN1B 16p12.2-p12.1 NM_000336 Pseudohypoaldosteronism 
type 1
Pseudoaldosteronism 
(Liddle syndrome)
37 Renal salt loss increased
Renal sodium uptake
Shimkets and 
cols., 1994 (14)
ENaCγ SCNN1G 16p12 NM_001039 Pseudohypoaldosteronism 
type 1
Pseudoaldosteronism 
(Liddle syndrome)
15 Renal salt loss increased
Renal sodium uptake
Hansson and 
cols., 1995 (15)
TRPM6 TRPM6 9q21.13 NM_017662 Hypomagnesemia with 
secondary hypocalcemia 
35 Renal magnesium loss 
Decrease serum 
concentration of calcium
Schlingmann and 
cols., 2002 (20) 
Walder and cols., 
2002 (19)
Kir1.1 KCNJ1 11q24 NM_000220 Bartter syndrome type II 51 Renal salt loss Simon and cols., 
1996 (23)
hClC-Kb CLCNKB 1p36.13 NM_000085 Bartter syndrome type III 37 Renal salt loss Simon and cols., 
1997 (24)
Kir6.2 KCNJ11 11p15.1 NM_000525 Persistant hyperinsulinemic 
hypoglycemia of infancy 
Neonatal diabetes mellitus 
82 Insulin hypersecretion 
Insulin hyposecretion
Thomas and 
cols., 1996 (29)
SUR1 ABCC8 11p15.1 NM_000352 Persistant hyperinsulinemic 
hypoglycemia of infancy 
Neonatal diabetes mellitus 
243 Insulin hypersecretion Thomas and 
cols., 1995 (28)
CFTR CFTR 7q31.2 NM_000492 Cystic fibrosis 1489 Altered epithelial transport Riordan and 
cols., 1989 (35)
CLC-5 CLCN5 Xp11.23-p11.22 NM_000084 Dent’s disease 134 Impaired endosome 
acidification
Fisher and cols., 
1995 (42)
CLCN7 CLCN7 16p13 NM_001287 Osteopetrosis 57 Impaired bone resorption Kornak and cols., 
2001 (46)
AQP2 AQP2 12q12-q13 NM_000486 Nephrogenic diabetes 
insipidus
46 Renal water loss van Lieburg and 
cols., 1994 (53)
Kir2.6 KCNJ18 17p11.1-2 NW_003315950 Thyrotoxic hypokalemic 
Periodic Paralysis
6 Hypokalemia due to 
T3-excess inducing 
increased K+ shift
Ryan and cols., 
2010 (8)
Figure 1. Schematic illustration of an endocrine cell action potential. The major electrophysiological features of ion currents (I) are illustrated throughout 
the waveform phase 1-4. 1- K+ channel closed (KATP in b-cell); Increase ICa2+ (VDCC) from outside membrane; then more Ca2+ from ER run to cytoplasm. 
2- Quick K+ goes out (Ito) and relatively more K+ leaves cell (IKr, IKs, IKur); Ca
2+-activated K+ channel opens; less Ca2+ in, increase SERCA pump activity (Ca2+ 
returns to ER). 3- Increase IKir out and Cl
- influx. 4-Excess K+ outside diffuses away; increase Na+/K+-ATPase pump. 
VDCC voltage-dependent calcium channel; ER endoplasmic reticulum; ITO transient outward current of voltage-gated K
+ channel; IKr, IKs, IKur are major repolarising currents of outwardly rectifying K
+ 
channels (IK), which can be divided into ultrarapid (IKur), rapid (IKr) and slow (IKs) components; SERCA is a ER Ca
2+ pump Sarco(Endo)plasmic Reticulum Ca2+-ATPase.
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Figure 2. Excitation-contraction coupling of skeletal muscle. In TPP, loss 
of function of the Kir channel decreases outward potassium current leading 
to depolarization and loss of muscle excitability. DHP: dihydropyridine 
receptor; RyR: ryanodine receptor; SR: sarcoplasmic reticulum.
Pseudohypoaldosteronism (PHA) type 1 
PHA type 1 is a rare salt-wasting disorder that was first 
described in 1958. It is associated with a decreased re-
sponse to aldosterone. Symptoms include dehydration, 
hyponatremia, hypokalemia, metabolic acidosis and 
failure to thrive in the neonatal period (17). Plasma re-
nin and aldosterone concentrations are grossly elevated 
due to a peripheral resistance to mineralocorticoids. 
Glomerular filtration, renal and adrenal functions, 
however, are normal. PHA is suspected when patients 
fail to respond to mineralocorticoid therapy (18).
This disease has two distinct forms with different 
physiologic and genetic characteristics: the renal form 
of PHA type 1 can be inherited either as an autosomal 
dominant (AD) trait or as a generalized autosomal reces-
sive (AR) trait. Inactivating mutations in the mineralo-
corticoid receptor cause the autosomal dominant form 
of PHA type 1 (19), while the AR form is caused by inac-
tivating mutations in α, b and γ subunits of the epithelial 
sodium channel (ENaC). The AR form is an ion chan-
nelopathy and is the more severe form of this disease.
ENaC is expressed in the apical plasma membrane 
of many epithelial tissues, and aldosterone resistance is 
seen in many tissues, including sweat glands, salivary 
glands, respiratory tract, colonic mucosa and kidneys. 
ENaC subunit genes are SCNN1A, SCNN1B and 
SCNN1G (18,20-22). Most reported mutations in 
these genes are frameshift or nonsense, leading to non-
functioning proteins. Unlike the AD form, the AR con-
dition does not spontaneously improve with age and, 
thus, requires lifelong therapy and treatment. 
Liddle syndrome
Liddle syndrome was first described in 1963. It is an 
inherited autosomal dominant form of endocrine hy-
pertension (23). Affected patients present with hy-
pertension, hypokalemia and metabolic alkalosis (23). 
Hypertension frequently begins in childhood but can 
be asymptomatic and may not be detected until early 
adulthood. Plasma renin activity and aldosterone levels 
are low. This disease is caused by activating mutations 
of the epithelial sodium channel (ENaC), which leads 
to an endocrine hypertensive disorder due to increased 
sodium reabsorption and potassium wasting in the distal 
nephron. 
Liddle syndrome is caused by mutations in SCNN1B 
or SCNN1G genes, which truncate the cytoplasmic car-
boxyl terminus of the b (SCNN1B) and γ (SCNN1G) 
subunits of the epithelial sodium channel (ENaC) 
(24). These mutations lead to ENaC gain-of-function 
through two mechanisms: enhancement of the channel 
activity by increasing the probability of opening and, 
most importantly, increasing the number of function-
ing channels by slowing degradation (25). Treatment 
involves a low-salt diet and the use of drugs, such as 
amiloride and triamterene, that directly inhibit epithe-
lial sodium transport (23). It is important to point out 
that mineralocorticoid receptor antagonists, such as 
spironolactone, are ineffective.
Hypomagnesemia with secondary hypocalcemia
Familial hypomagnesemia with secondary hypocal-
cemia is an autosomal recessive disease that results in 
electrolyte abnormalities shortly after birth. Affected 
individuals show severe hypomagnesemia and sec-
ondary hypocalcemia, leading to seizures and muscle 
cramps (26,27). If left untreated, the disorder can re-
sult in neurological damage and death. Hypocalcemia 
is secondary to parathyroid failure as a consequence of 
magnesium deficiency (27).
Hypomagnesemia with secondary hypocalcemia is 
caused by mutations in the transient receptor potential 
cation channel, subfamily M, member 6 (TRPM6) (26, 
Ion channelopathies in endocrinology
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27). TRPM6 is expressed in the intestinal mucosa and 
the kidney. It encodes for a protein that functions as 
both a protein kinase and a calcium and magnesium 
ion channel. Affected patients have abnormal intestinal 
absorption and renal excretion of magnesium (26).
Patients require life-long treatment with magne-
sium supplementation.
Bartter syndrome 
Bartter syndrome (BS) is an inherited salt-losing re-
nal tubulopathy characterized by hypokalemic meta-
bolic alkalosis, normal to low blood pressure and el-
evated renin and aldosterone levels (28,29). Affected 
patients often present with polyhydramnios during 
pregnancy or polyuria and dehydration in early child-
hood. This disorder is caused by dysfunctional renal 
tubular electrolyte transporters in the thick ascending 
limb (TAL) of the nephron. There are five different 
types of Bartter syndrome that are correlated with 
predominantly autosomal recessive gene mutations. 
Urine samples in patients with Bartter syndrome 
show elevated levels of prostaglandins (e.g., PGE2). 
Patients with BS types I, II or IV have isosthenuria or 
hyposthenuria. In addition to renal dysfunction, BS 
type IV patients experience sensorineural deafness. 
Patients with BS type I or II have hypermagnesiuria 
and hypercalciuria. BS type III is typically the mildest 
of the five BS types (29).
In BS type I, the affected gene, SCL12A1, encodes 
the apical furosemide-sensitive sodium potassium chlo-
ride cotransporter (NKCC2). NKCC2 arises on the 
TAL luminal membrane and reabsorbs sodium together 
with one potassium and two chloride ions (Figure 3). 
SCL12A1 mutations result in active transtubular salt 
transport defects. BS type II results from mutation in 
the inwardly-rectifying potassium channel, subfamily J, 
member 1 (KCNJ1) gene (30). KCNJ1 encodes the api-
cal renal outer medullary K+ (ROMK1) channel, which 
is required for adequate recirculation of potassium into 
the luminal space. It also provides the driving force for 
paracellular absorption of calcium and magnesium. So-
dium exits through NaK-ATPase and chloride exits via 
Cl- channel K+ proteins (ClC-Ka and ClC-Kb) on the 
basolateral side. These chloride channels require a func-
tioning Barttin subunit for proper membrane localiza-
tion. Mutations in BSDN, the gene that encodes Bart-
tin, affect chloride channels and cause BS type IV. BS 
type III, also called classic Bartter’s syndrome, is caused 
by ClC-Kb (CLCNKB) gene mutations (28,29,31). 
Figure 3. Ion transepithelial transport in thick ascending limb cells 
(adapted from reference 29). NKCC2: sodium potassium chloride 
cotransporter; ClCKA: channel K+ protein A; ClCKB: channel K+ protein B; 
ROMK1: renal outer medullary K+.
BS type V, an autosomal dominant form of Bartter 
syndrome, is caused by a gain-of-function mutation in 
the extracellular basolateral calcium sensing receptor 
(CASR) gene (32). CASR is essential for regulating se-
cretion of parathyroid hormone (PTH) but is also ex-
pressed in other tissues, such as the kidney. Activation of 
CASR inhibits ROMK1 activity, which leads to hypocal-
cemic hypercalciuria and low PTH levels. 
Persistent hyperinsulinemic hypoglycemia of infancy 
(HHI)
Persistent hyperinsulinemic hypoglycemia of infancy 
(HHI), also named congenital hyperinsulinism, is the 
most common cause of nontransient hyperinsulinemic 
hypoglycemia in neonates and infants (33). Typical 
clinical signs, including hypoglycemia, lethargy, poor 
feeding and irritability, arise shortly after birth. Some 
newborns may show more severe symptoms including 
seizures and coma that, if not recognized and treated 
properly, can cause severe mental retardation and epi-
lepsy (33). Diagnosis is based on the detection of non-
ketotic hypoglycemia with low serum fatty acid levels, 
inappropriately high insulin levels and raised C-peptide 
levels. Glucose levels are also known to rise in response 
to glucagon administration in affected infants (4).
The most common causes of persistent HHI are 
inherited autosomal recessive mutations that inactivate 
ABCC8 and KCNJ11 genes (34,35). The pancreatic 
KATP channel is a functional complex of four sulfonyl-
urea receptors 1 (SUR1) and four pore-forming inward 
rectifier potassium channel subunits (Kir 6.2). The KATP 
Ion channelopathies in endocrinology
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channel is a critical regulator of beta-cell insulin secre-
tion. KCNJ11 encodes for Kir6.2 and ABCC8 encodes 
for SUR1. ABCC8 mutations are associated with 50–
60% of persistent HHI cases, while KCNJ11 mutations 
account for about 10%-15% of patients (5).
Inactivating mutations result in persistent b-cell 
membrane depolarization and insulin secretion, despite 
low plasma glucose levels. At the molecular level, these 
mutations cause multiple abnormalities in KATP channels 
turnover, regulation and open-state frequency (4,5). 
neonatal diabetes mellitus
Hyperglycemia during the first six months of life is defined 
as neonatal diabetes (NDM). NDM is associated with 
slowed intrauterine growth, failure to thrive, low birth 
weight, decreased adipose tissue and low or undetect-
able C-peptide levels. Most patients are markedly hyper-
glycemic and some present with ketoacidosis (36). This 
rare disorder has two forms: transient NDM (TNDM) 
and permanent NDM (PNDM). Unfortunately, there 
is no clinical distinction between these two forms at the 
time of presentation. In approximately 50%-60% of cases, 
TNDM resolves usually within three months (37). 
Most TNDM cases (70%) are due to abnormali-
ties on chromosome 6 (6q24), while PNDM is most 
commonly caused by genetic variations in KATP channel 
genes. Activating KCNJ11 gene mutations (Kir6.2 sub-
unit of the KATP channel) account for 31%-64% of cases 
of PNDM (37). Less commonly, KCNJ11 mutations 
are associated with TNDM or a multisystem disease, 
DEND syndrome (developmental delay, epilepsy and 
neonatal diabetes). Mutations in ABCC8 gene (SUR 
subunit) are primarily associated with TNDM. 
In healthy individuals, the presence of glucose leads to 
intracellular ATP production, which results in KATP chan-
nel closure and membrane depolarization. This, in turn, 
leads to calcium influx and insulin secretion (5,36,37). 
Activating mutations in KATP channels decrease sensitiv-
ity to ATP inhibition, which causes them to remain open 
in the presence of glucose and reduce insulin secretion. 
Sulfonylureas can bind to the SUR1 subunit and closing 
the KATP channel and, thus, can be used to treat patients 
with ND activating KATP channel mutations (5). 
cystic fibrosis
Cystic fibrosis (CF) is the most common autosomal 
recessive disorder in Caucasians, with a frequency of 
about 1 in 2,500 live births. Clinical manifestations 
include pulmonary infection, pancreatic insufficiency, 
elevated chloride levels in sweat, infertility and pseudo-
Bartter’s syndrome (salt wasting with metabolic alka-
losis) (38). Lung disease is the main cause of morbid-
ity and mortality. Exocrine pancreatic insufficiency is 
present in 85%-90% of cases and is thought to result 
from reduced volume of pancreatic secretion with low 
concentrations of HCO3, which cause retention and 
premature activation of digestive proenzymes, which 
results in tissue destruction and fibrosis (38). This and 
other concurrent processes that are poorly understood 
may lead to b-cell death and result in diabetes mellitus. 
Diabetes mellitus is rare in the first decade of life and 
its prevalence increases with age. Insulin sensitivity is 
diminished in patients with CF due to a number of fac-
tors, including chronic infection and inflammation and 
systemic steroid use. There are conflicting data, how-
ever, with regard to the role of insulin resistance in the 
etiology of cystic fibrosis-related diabetes mellitus (39). 
CF is caused by a mutation in the cystic fibrosis trans-
membrane conductance regulator gene (CFTR) that 
produces a defective chloride channel in epithelial mem-
branes (40). The disease phenotype varies according to 
the type of mutation and the presence of gene modifiers, 
such as transforming growth factor beta-1 and mannose-
binding lectin 2 genes (41). Over 1,800 CFTR muta-
tions have been described thus far (42). These muta-
tions are divided into five different classes that represent 
a gradient of CFTR dysfunction, with class I indicating 
defective protein production and class V indicating pro-
duction of reduced functioning CFTR protein. Class 
1-3 mutations are the most common and are associated 
with pancreatic insufficiency, whereas patients with class 
4 or 5 do not have pancreatic insufficiency. The most 
common CFTR mutation in patients with cystic fibrosis-
related diabetes mellitus is Phe508del (39). 
A concentration in sweat chloride greater than 60 
mmol/L on repeated analysis is diagnostic. In cases of 
marginal sweat test results, CFTR genotyping is recom-
mended (38); however, some suggest DNA testing in 
individuals with positive sweat test.
Neonatal screening for cystic fibrosis is carried out 
in some countries. It is unclear whether early diagnosis 
improves long-term outcomes, but there is evidence to 
suggest that there are nutritional benefits (43).
Dent’s disease 
Dent’s disease is a X-linked recessive proximal renal tu-
bular syndrome characterized by low-molecular-weight 
Ion channelopathies in endocrinology
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proteinuria, hypercalciuria, nephrocalcinosis, meta-
bolic bone disease and progressive renal failure (44). 
Approximately 25% of affected males also have rickets 
or osteomalacia, with deforming bone disease in child-
hood (44,45). Interestingly, the occurrence of rickets 
varies between affected members of the same family as 
well as between different families with the same muta-
tion. It is unknown whether this variability is due to 
modifying genes or environmental factors (45).
Sixty percent of Dent’s disease cases are caused by 
mutations in the chloride channel gene, CLCN5, that 
encodes the chloride-proton antiporter, CLC-5 (46). 
CLC-5 is found primarily in the kidneys and is expressed 
with proton-ATPase in subapical endosomes of the tu-
bular proximal cells where it facilitates acidification (47). 
Acidification is necessary to process proteins taken up by 
endosomes. Thus, loss of function CLC-5 mutations that 
impair acidification of vesicles in the endocytotic pathway 
are responsible for proteinuria seen with Dent’s disease 
(47). In 15 percent of cases, the disease is associated with 
mutations in the OCRL1 gene, that is also mutated in 
the oculocerebrorenal syndrome of Lowe (48). In some 
patients presenting with symptoms of Dent’s disease, no 
CLCN5 and OCRL1 mutations were found, which sug-
gests further genetic heterogeneity is involved. 
Osteopetrosis
Mutations in the gene that encodes the chloride chan-
nel-7 protein (CLCN7) can cause autosomal dominant 
osteopetrosis type II (Albers-Schönberg disease) and 
autosomal recessive osteopetrosis type IV (infantile os-
teopetrosis) (49,50).
Infantile osteopetrosis is a rare autosomal reces-
sive disorder in which failure to resorb bone and cal-
cified metaphyseal cartilage causes near obliteration of 
the marrow spaces (49). About 15% of these patients 
have genetic defects on the osteoclast chloride channel 
(CLCN7), while 60% of the cases are due to mutations 
in the subunits of the vascular-type H+-adenosine tri-
phosphatase (51). 
Autosomal dominant osteopetrosis type II is char-
acterized by generalized osteosclerosis with thicken-
ing of the vertebral endplates and pelvic bone. Clinical 
manifestations include fractures, osteoarthritis, skeletal 
deformities and cranial nerve involvemement (52). 
The characterization of genetic defects in osteo-
petrosis opens up the possibility for gene replacement 
therapy as an alternative to hematopoietic stem cell 
transplantation in children with severe disease (53). 
nephrogenic diabetes insipidus 
In nephrogenic diabetes insipidus (NDI), the distal 
nephron is insensitive to antidiuretic hormone (ADH), 
decreasing the ability of the kidney to concentrate urine. 
If fluid intake is not sufficient to compensate for the 
increased water loss, patients may experience dehydra-
tion and electrolyte imbalance. Acquired causes include 
drugs, especially lithium toxicity, renal disease, hyper-
calcemia and hypokalemia (54). Hereditary NDI is rare 
and is usually diagnosed soon after birth or in early 
childhood (55). In the majority of cases, NDI is caused 
by mutations in the vasopressin receptor (V2) gene and 
in the aquaporin-2 (AQP2) gene (56). However, since 
mutations in the above mentioned genes were not found 
in some affected families, other genes may be involved. 
With AQP2 mutations, both recessive and dominant in-
heritance patterns have been reported (55). 
AQP2 is expressed primarily in principal cells of the 
collecting ducts of renal tubules where regulated water 
reuptake is known to occur (57). Under the influence 
of ADH, the vesicles with AQP2 traffic to the lumi-
nal membrane, increasing the water permeability of the 
collecting duct and allowing water to be reabsorbed 
along the concentration gradient.
Elucidation of the mutations and mechanisms re-
sponsible for NDI is important for the development of 
therapeutic approaches, such as molecules to help di-
rect AQP2 to the cell surface (58). 
PeRSPectIveS: cHAnneLS cOntROLLInG tRH-
InDUceD PROLActIn SecRetIOn AnD OvARY 
SteROIDOGeneSIS
As with other neuroendocrine cells, hormone secre-
tion from anterior pituitary lactotrophs is regulated 
by changes in their excitability. Thyroid releasing hor-
mone (TRH) stimulates prolactin secretion through 
membrane depolarization. Membrane depolarization 
can be accompanied by an increase in the rate of action 
potential firing leading to an increase in intracellular 
Ca2+ content. In lactotroph cells, an inwardly rectifying 
K+ (Kir) current contributes to the maintenance of the 
resting potential and is blocked by TRH. In these cells, 
K+ current is typically carried by ether-à-go-go (erg) re-
lated K+ channels. Erg channels are voltage-dependent 
K+ channels that mediate Kir currents by shifting the 
membrane potential towards the K+ equilibrium poten-
tial with small outward currents (59). TRH-induced 
reduction of the K+ erg current is mediated by a G pro-
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tein-coupled intracellular signal cascade. Elucidation of 
this pathway may allow the development of new drugs 
to target the erg K+ current (60) and, consequently, 
limit TRH-induced pathological hyperprolactinemia.
Another promising field has emerged from Kunz’s 
study (10). The authors showed that the activity of Ca2+-
activated K+ channel (BKCa), present in luteinized granu-
losa cells of the ovary, plays a prominent role in the ces-
sation of Ca2+-induced cellular responses by repolarizing 
the plasma membrane. These BKCa channels mediate in-
traovarian signaling and are regulated in vitro by oxyto-
cin and acetylcholine. These findings suggest that there 
is an interaction between systemic hormones and the lo-
cal neuroendocrine system in control of steroidogenesis.
cOncLUSIOn
There is growing interest in understanding ion chan-
nel diversity in endocrine cells. This interest stems, in 
part, from the role many of these ion channels play in 
hormone secretion (b-cells), mechanotransduction and 
acidification (chondrocytes), hormonal excess toxicity 
(neuromuscular junction), chemotransduction (ovarian 
and gonadotroph cells) and osmoregulation (neurohy-
pophyseal cells). A few research groups, including ours, 
have focused on the molecular biology of endocrine ion 
channel disorders to help physicians make molecular di-
agnoses of rare endocrine channelopathies. It is likely 
that some ion channels in endocrine cells are multifunc-
tional, serving a number of different physiological pur-
poses involved, primarily, with metabolic regulation. In 
summary, ion channels play an important role in me-
diating the endocrine system by firing, controlling and 
hormonally tuning specialized cellular functions. This 
knowledge will help us understand the unique biology 
of excitable endocrine cells that can lead to the devel-
opment and formulation of new therapeutic strategies 
to treat endocrine diseases.
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